What is the price of Talazoparib covered by medical insurance in 2025?
Talazoparib (Talazoparib), as a PARP inhibitor, has been officially launched in China. Patients can purchase this drug through local hospital pharmacies. Nonetheless, domestic medical insurance coverage of talazoparib may vary from region to region. Specific medical insurance reimbursement policies and reimbursement ratios require patients to consult in detail with the hospital or medical insurance department in their region to ensure reasonable arrangements for medication costs.
From a price perspective, the domestic selling price of talazoparib is relatively high. Taking the specification of 0.25mg 30 tablets as an example, the latest market price is usually around more than 10,000 yuan, while the price of 1mg 30 tablets is even higher and may reach more than 50,000 yuan. Such a price reflects the drug's high R&D costs and advanced therapeutic value as a targeted anti-cancer drug, but for some patients, the economic burden is still heavy.

In overseas markets, multiple versions of talazoparib are also available. The Hong Kong version and the European version of the original drug are equally expensive, especially the high-dose specifications, which are much higher than the domestic market. In contrast, the price of generic versions of drugs in Laos is relatively affordable, with the latest price of 1mg*30 capsules being about 4,000 yuan. Although generic drugs are cheap, their active ingredients are basically the same as the original drugs, making them an important choice for some patients.
To sum up, talazoparib has been launched in China and is gradually included in some medical insurance coverage. Patients should pay attention to the latest changes in medical insurance policies when purchasing the drug and reasonably arrange treatment costs. At the same time, patients can also choose appropriate drug specifications and purchase channels based on their own conditions and doctor's recommendations to ensure continuity of treatment and affordability.
Reference materials:https://www.talzenna.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)